Getein Biotech

Getein Biotech Working Capital

The Working Capital of Getein Biotech (603387.SS) as of Nov 6, 2026 is 478.13 M CNY. In the previous year, Working Capital was 865.29 M CNY — a change of -44.74% (lower).

Working Capital

478.13 MCNY

YoY

-44.74%

Last updated:

Working Capital of Getein Biotech is 2025 478.13 M CNY. Working Capital of Getein Biotech was 2024 865.29 M CNY. It decreases by -44.74% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Getein Biotech Stock analysis

What does Getein Biotech do? Getein Biotech Inc generates revenue through the sale of in vitro diagnostic reagents and diagnostic instruments. The company offers POCT reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, and hemagglutination reagents. Diagnostic instruments include the FIA 8000 and FIA 8600 immunoquantitative analyzers, Getein 1100 and Getein 1180 fluorescence immunoquantitative analyzers, CM 400 automatic biochemical analyzer, MAGICL 6000 automatic chemiluminescence analyzer, and BHA-5000 five classification blood cell analyzer. The firm also provides testing and agency services. Products are distributed domestically and to overseas markets. The primary buyers of Getein Biotech's products include healthcare facilities, laboratories, and medical institutions within China and international markets. Domestic sales focus on the Chinese healthcare sector, while overseas markets extend to global customers seeking diagnostic solutions. The company's reagent and instrument portfolio targets hospitals, clinics, and diagnostic centers requiring reliable testing equipment and consumables. Getein Biotech's revenue streams are derived from direct sales of its diagnostic reagents and instruments, as well as service-based offerings like testing and agency services. The company's product range caters to both domestic and international healthcare providers, with a strong emphasis on in vitro diagnostic solutions for blood analysis, chemiluminescence, and biochemical testing. The firm's distribution strategy ensures its products reach medical facilities across China and internationally. Getein Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Getein Biotech stock

Working Capital of Getein Biotech is 478.13 M CNY in 2025.

Working Capital of Getein Biotech changed from 865.29 M CNY to 478.13 M CNY, representing a -44.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Getein Biotech since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's Getein Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Getein Biotech

All Key Metrics — Getein Biotech